HRP20201316T1 - Novi modulatori receptora sfingozin-fosfata - Google Patents
Novi modulatori receptora sfingozin-fosfata Download PDFInfo
- Publication number
- HRP20201316T1 HRP20201316T1 HRP20201316TT HRP20201316T HRP20201316T1 HR P20201316 T1 HRP20201316 T1 HR P20201316T1 HR P20201316T T HRP20201316T T HR P20201316TT HR P20201316 T HRP20201316 T HR P20201316T HR P20201316 T1 HRP20201316 T1 HR P20201316T1
- Authority
- HR
- Croatia
- Prior art keywords
- pharmaceutically acceptable
- compound
- pharmaceutical preparation
- stereoisomer
- solvate
- Prior art date
Links
- WWUZIQQURGPMPG-UHFFFAOYSA-N (-)-D-erythro-Sphingosine Natural products CCCCCCCCCCCCCC=CC(O)C(N)CO WWUZIQQURGPMPG-UHFFFAOYSA-N 0.000 title 1
- 229910019142 PO4 Inorganic materials 0.000 title 1
- 239000010452 phosphate Substances 0.000 title 1
- WWUZIQQURGPMPG-KRWOKUGFSA-N sphingosine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO WWUZIQQURGPMPG-KRWOKUGFSA-N 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- 150000001875 compounds Chemical class 0.000 claims 6
- 239000000825 pharmaceutical preparation Substances 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 201000006417 multiple sclerosis Diseases 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 239000012453 solvate Substances 0.000 claims 4
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 2
- 102000011011 Sphingosine 1-phosphate receptors Human genes 0.000 claims 2
- 108050001083 Sphingosine 1-phosphate receptors Proteins 0.000 claims 2
- 230000004913 activation Effects 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 2
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 239000000443 aerosol Substances 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12760308P | 2008-05-14 | 2008-05-14 | |
| EP15158887.8A EP2913326B1 (en) | 2008-05-14 | 2009-05-14 | Novel modulators of sphingosine phosphate receptors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20201316T1 true HRP20201316T1 (hr) | 2020-11-27 |
Family
ID=43426295
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20201316TT HRP20201316T1 (hr) | 2008-05-14 | 2020-08-24 | Novi modulatori receptora sfingozin-fosfata |
Country Status (12)
| Country | Link |
|---|---|
| KR (2) | KR20150064245A (lt) |
| CN (1) | CN102118972B (lt) |
| BR (1) | BRPI0912545B1 (lt) |
| CA (1) | CA2723904C (lt) |
| DK (1) | DK2913326T3 (lt) |
| HR (1) | HRP20201316T1 (lt) |
| HU (1) | HUE050411T2 (lt) |
| IL (1) | IL209306A (lt) |
| LT (1) | LT2913326T (lt) |
| MX (1) | MX2010012461A (lt) |
| SI (1) | SI2913326T1 (lt) |
| ZA (1) | ZA201007804B (lt) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5837417B2 (ja) | 2008-05-14 | 2015-12-24 | ザ スクリプス リサーチ インスティテュート | スフィンゴシンリン酸受容体の新規なモジュレーター |
| WO2015196258A1 (en) * | 2014-06-26 | 2015-12-30 | Monash University | Enzyme interacting agents |
| CN109219597A (zh) | 2016-06-14 | 2019-01-15 | 苏州科睿思制药有限公司 | 奥扎莫德的晶型、其盐酸盐的晶型及其制备方法 |
| EP3502100A1 (en) | 2016-08-19 | 2019-06-26 | Crystal Pharmaceutical (Suzhou) Co., Ltd. | Crystal forms of ozanimod and preparation method therefor |
| US10882830B2 (en) | 2016-09-14 | 2021-01-05 | Receptos Llc | Crystal form of ozanimod hydrochloride and processes for preparation therefor |
| CN108137516A (zh) | 2016-09-14 | 2018-06-08 | 杭州领业医药科技有限公司 | 奥扎莫德的晶型、其制备方法及药物组合物 |
| CN106749213B (zh) * | 2016-11-25 | 2019-07-02 | 济南大学 | 一种具有1,2,4-恶二唑结构的吲哚衍生物及制备方法和在制备抗菌药物中的应用 |
| US11117876B2 (en) | 2017-08-31 | 2021-09-14 | Receptos Llc | Crystalline form of ozanimod hydrochloride, and processes for preparation thereof |
| CN107827837B (zh) * | 2017-11-21 | 2021-09-24 | 苏州朗科生物技术股份有限公司 | 鞘氨醇-1-磷酸受体调节剂化合物及其制备方法与应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7220734B2 (en) * | 2002-12-20 | 2007-05-22 | Merck & Co., Inc. | 1-(amino)indanes and (1,2-dihydro-3-amino)-benzofurans, benzothiophenes and indoles as Edg receptor agonists |
| WO2007116866A1 (ja) * | 2006-04-03 | 2007-10-18 | Astellas Pharma Inc. | ヘテロ化合物 |
-
2009
- 2009-05-14 MX MX2010012461A patent/MX2010012461A/es active IP Right Grant
- 2009-05-14 CA CA2723904A patent/CA2723904C/en active Active
- 2009-05-14 LT LTEP15158887.8T patent/LT2913326T/lt unknown
- 2009-05-14 SI SI200932087T patent/SI2913326T1/sl unknown
- 2009-05-14 KR KR1020157013971A patent/KR20150064245A/ko not_active Application Discontinuation
- 2009-05-14 CN CN200980127478.8A patent/CN102118972B/zh active Active
- 2009-05-14 BR BRPI0912545-0A patent/BRPI0912545B1/pt active IP Right Grant
- 2009-05-14 KR KR1020107028062A patent/KR101582910B1/ko active IP Right Grant
- 2009-05-14 DK DK15158887.8T patent/DK2913326T3/da active
- 2009-05-14 HU HUE15158887A patent/HUE050411T2/hu unknown
-
2010
- 2010-11-01 ZA ZA2010/07804A patent/ZA201007804B/en unknown
- 2010-11-14 IL IL209306A patent/IL209306A/en active Protection Beyond IP Right Term
-
2020
- 2020-08-24 HR HRP20201316TT patent/HRP20201316T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HUE050411T2 (hu) | 2020-12-28 |
| KR101582910B1 (ko) | 2016-01-08 |
| DK2913326T3 (da) | 2020-08-17 |
| ZA201007804B (en) | 2012-01-25 |
| LT2913326T (lt) | 2020-09-10 |
| MX2010012461A (es) | 2013-07-02 |
| IL209306A0 (en) | 2011-01-31 |
| CA2723904A1 (en) | 2009-12-17 |
| BRPI0912545B1 (pt) | 2022-02-01 |
| KR20110010777A (ko) | 2011-02-07 |
| KR20150064245A (ko) | 2015-06-10 |
| CN102118972A (zh) | 2011-07-06 |
| BRPI0912545A2 (pt) | 2021-04-13 |
| CA2723904C (en) | 2017-03-14 |
| IL209306A (en) | 2017-02-28 |
| SI2913326T1 (sl) | 2020-11-30 |
| CN102118972B (zh) | 2015-06-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20201316T1 (hr) | Novi modulatori receptora sfingozin-fosfata | |
| HRP20150982T1 (hr) | Novi modulatori sfingozin fosfat receptora | |
| HRP20160189T1 (hr) | Liječenje crohnove bolesti lakvinimodom | |
| HRP20150770T1 (hr) | Terapijska kombinacija koja sadrži dolutegravir, abakavir i lamivudin | |
| AU2018278332A1 (en) | Methods and compositions for treating excessive sleepiness | |
| PH12015502134A1 (en) | Mosapride sustained-release preparation for providing pharmacological and clinical effects with once-a-day administration | |
| HRP20120323T4 (hr) | Spoj diaril-hidantoina | |
| HRP20151357T1 (hr) | Upotreba äśestica äśvrstog nosaäśa kako bi se poboljšala procesabilnost farmaceutskog agensa | |
| JP2009525343A5 (lt) | ||
| JP2013199505A5 (lt) | ||
| JP2011068653A5 (lt) | ||
| WO2011107855A3 (en) | Sustained release oral liquid suspension dosage form | |
| JP2015529234A5 (lt) | ||
| JP2012255026A5 (lt) | ||
| JP2015522630A5 (lt) | ||
| JP2010527347A5 (lt) | ||
| NZ613291A (en) | Treatment of cognitive disorders with (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof | |
| KR20160112012A (ko) | 질내 투여용 속용성 정제 조성물 | |
| JP2013516493A5 (lt) | ||
| MX2011008188A (es) | Composicion farmaceutica para administracion oral. | |
| HRP20171742T4 (hr) | 2,4,6-trifluor-n-[6-(1-metilpiperidin-4-karbonil)piridin-2-il]benzamid, namijenjen liječenju migrene oralnom ili intravenskom primjenom | |
| NZ587202A (en) | Methods for measuring a patient response upon administration of a drug and compositions thereof | |
| JP2021505575A5 (lt) | ||
| NZ700924A (en) | Dosage regimen for a pi-3 kinase inhibitor | |
| BR112014014795A2 (pt) | sistema de pélete de multiunidade de liberação imediata |